[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"norm-eurlex-emir-erwgr-79-de":3},{"law":4,"norm_id":14,"norm_key":15,"slug":16,"title":17,"chapter":18,"content":19,"enriched_content":20,"hierarchy":21,"neighbors_before":22,"neighbors_after":32,"citing_decisions":42,"is_thin":43},{"abbreviation":5,"title":6,"source_type":7,"jurisdiction":8,"document_kind":9,"language":10,"attribution":11,"version_date":12,"source_url":13},"emir","über OTC-Derivate, zentrale Gegenparteien und Transaktionsregister","eurlex","eu","regulation","de","© Europäische Union, https:\u002F\u002Feur-lex.europa.eu","2025-07-12","https:\u002F\u002Feur-lex.europa.eu\u002Flegal-content\u002FDE\u002FALL\u002F?uri=CELEX:32012R0648",13373612,"ErwGr. 79","erwgr-79",null,"Erwägungsgründe","Im Interesse einer wirksamen Ausübung ihrer Aufsichtsbefugnisse sollte die ESMA in der Lage sein, Untersuchungen und Prüfungen vor Ort durchzuführen.","EMIR - Erwägungsgründe - ErwGr. 79\n\nIm Interesse einer wirksamen Ausübung ihrer Aufsichtsbefugnisse sollte die ESMA in der Lage sein, Untersuchungen und Prüfungen vor Ort durchzuführen.",{},[23,26,29],{"norm_key":24,"title":17,"slug":25},"ErwGr. 78","erwgr-78",{"norm_key":27,"title":17,"slug":28},"ErwGr. 77","erwgr-77",{"norm_key":30,"title":17,"slug":31},"ErwGr. 76","erwgr-76",[33,36,39],{"norm_key":34,"title":17,"slug":35},"ErwGr. 80","erwgr-80",{"norm_key":37,"title":17,"slug":38},"ErwGr. 81","erwgr-81",{"norm_key":40,"title":17,"slug":41},"ErwGr. 82","erwgr-82",[],true]